Leap Therapeutics undergoes strategic restructuring to prioritize clinical development of sirexatamab in CRC resulting in an approximately 50% reduction in workforce May 21, 2025
Statistically Significant Topline Results from Global Ph 2 Trial of Elraglusib in 1L Treatment of Metastatic Pancreatic Cancer Announced May 13, 2025
Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Ph 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in 1L Metastatic Pancreatic Cancer Patients May 13, 2025
IND application submitted to the U.S. FDA for UTRxM1-18 for targeting c-MYC driven cancers May 13, 2025
Sandoz enters global collaboration license agreement with Henlius to commercialize ipilimumab in multiple indications May 6, 2025
Ph 2/3 trial of 2L+ KN026 + chemo in HER2-positive gastric/GEJ cancer met the primary endpoint of PFS at interim analysis May 6, 2025
Ph 1 study targeting GPC3 with 225Ac-GPC3 (BAY 3547926) in patients with advanced HCC initiated May 6, 2025
Full Results Announced From Completed Ph 1 Study of JNJ-1900 (NBTXR3) in Pancreatic Cancer May 6, 2025
CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer April 30, 2025
Enrollment completed in Ph 2 CRDF-004 Trial of Onvansertib in 1L RAS-mutated Metastatic CRC April 22, 2025
First Patient Enrolled in Ph 1b FORTRESS Trial of NG-350A in Locally Advanced Rectal Cancer Patients April 15, 2025
FDA Approves Opdivo + Yervoy as a Treatment for Patients with 1L MSI-H or dMMR Unresectable or Metastatic CRC April 15, 2025
Tovecimig (CTX-009) Meets Primary Endpoint in Ph 2/3 Study in Patients with Biliary Tract Cancer April 8, 2025
FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient March 26, 2025
Positive Topline Result for TEDOPaM Ph 2 trial of OSE2101 (Tedopi) in Advanced Pancreatic Cancer Announced March 18, 2025
FDA Clears IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic CRC March 18, 2025
EU authorises CTA to initiate VIDAR-1 Ph 1/2 umbrella trial in patients with mutated KRAS-positive advanced pancreatic cancer March 18, 2025
